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Abstract The ORLI O(.Opioid Receptor-Like) receptor is the G [10], a heptadecapeptide structurally related, however dis- 
protein-coupled receptor whose amino acid sequence is closest o tantly, to the opioid peptide dynorphin A. In recombinant 
those of opioid receptors. Residues that are conserved in ORL1 CHO cells expressing it, the ORLI receptor mediates inhibi- 
and the three types of opioid receptor, but also a residue, His in tion of adenylyl cyclase not only by nociceptin (which is not 
the sixth putative transmembrane (TM6) helix, which is present an opioid peptide) but also by etorphine [1] and other potent 
in all opioid receptor types but absent in ORL1, appear to play a opiates, such as lofentanil (Butour et al., manuscript in prep- 
key role in receptor recognition and/or activation. Here we have aration). Although the doses of opiate which maximally in- 
sought to create an opioid binding pocket in the non-opioid hibit the cyclase via ORLI are substantially higher than those 
ORLI receptor by replacing residue Gin 28° in its TM6 by the required to inhibit the enzyme via opioid receptors, the ORLI 
corresponding His residue of opioid receptors. The mutation receptor does recognize and respond to opiates, an indication 
affects neither the affinity of nociceptin - the natural ORL1 that the ORLI receptor contains a functional binding pocket 
agonist - for the receptor, nor the potency of nociceptin to inhibit 
whose structure resembles the opioid binding pocket of opioid adenylyl cyclase via ORL1. In contrast, we find that a few opioid 
ligands, the agonists lofentanil, etorphine and dynorphin A, and receptors. In practice then, it should be possible to improve 
especially the antagonists diprenorphine and nor-BNl, bind the the opioid binding abilities of the ORLI receptor, i.e. create 
mutant Q280H receptor with substantially (5- to > 100-fold) an opioid binding pocket in ORLI. by operating only minor 
higher apparent affinity than they do the wild-type receptor, changes in the amino acid sequence of the receptor. 
Moreover, iofentauil and etorpbine no longer act as pure There is abundant circumstantial evidence in favor of an 
agonists, as they do at the native ORL1 receptor, but are opiate binding pocket located within the bundle of transmem- 
endowed with clear antagonist properties at the mutant receptor, brane helices and common to the three types of opioid recep- 
The mutation Q280H, which increases affinity while decreasing tot'  (i) the putative membrane-spanning domains m ~t-, 8- and 
intrinsic activity of opioids at ORL1, emphasizes the importance ~c-opioid receptors display very high sequence homologies 
of the His residue for opioid recognition and activation. 
(->80% amino acid identity in TMs 2. 3 and 7), (ii) all endog- 
Key words: Opioid receptor; Nociceptin/orphanin FQ; enous opioid peptides contain the same Tyr-Gly-Gly-Phe 
Site-directed mutagenesis; Agonist/antagonist binding; opioid message sequence, and (iii) there are numerous rigid 
Adenylate cyclase inhibition opiates (the so-called 'universal' opiates) that bind the three 
types of opioid receptor as well as receptor chimeras thereof 
with comparable high affinities, for instance the two tetrahy- 
dro-endoethano-thebaine derivatives etorphine and diprenor- 
1. Introduction phine, and benzomorphans such as ethylketocyclazocine and 
bremazocine. Site-directed mutagenesis and 3-D models of 
The ORLI (Opioid Receptor-Like) receptor [1-8] is the G opioid receptors have begun to identify conserved amino 
protein-coupled receptor whose amino acid sequence is closest acid residues that may play a key role in opiate recognition 
to those of the ~, ~ and 1¢ types of opioid receptor. In parti- and/or receptor activation. These include not only residues 
cular, ORL1 and opioid receptors display extensive amino that are conserved in ORLI and the three types of opioid 
acid identity in their putative transmembrane (TM) helices receptor [I 1 14,18], but also and most interestingly, a residue 
(70-80% in TMs 2, 3 and 7). The ORL1 receptor endogenous which is present in all opioid receptor types but absent in 
ligand was recently identified as nociceptin [9] or orphanin FQ ORLI, namely His in the sixth putative transmembrane h lix 
(TM6). Then, substituting for His the corresponding amino 
acid residue (Gin 'es°) in ORL1 should endow the mutant 
ORLI receptor (Q280H) with increased binding affinity for 
opiates. Here, we have generated this mutant OREI receptor, 
have it stably' expressed in CHO cells, and compared its bind- 
*Corresponding author. Fax: (33) 61.17.59.94. ing and functional coupling properties with those of the native 
E-mail: manaute@ipbs.fr ORL1 receptor. We find thal opioid ligands bind the mutant 
Q280H receptor with substantially higher apparent affinity 
Abbreviations: ORL, opioid receptor-like; TM, transmembrane s g- than they do the wild-type receptor. Yet unexpectedly, these 
ment; G-protein, guanine nucleotide-binding regulatory proteins; opioids no longer act as pure a~onists, as they do at the native 
2 4 DAGO, [D-Ala',MePhe ,Gly-olY]enkephalin; DTLET, [D-Thr2,D - 
Leua]enkephalin; U-50488, trans,3,4-dichloro-N-methyl-N-[2-(1-pyrro- receptor, but are endowed with clear antagonist properties at 
lidinyl)cyclo-hexyl]-benzeneacetamide the mutant receptor. 
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2. Materials and methods initiated by addition of 20 lal of KRH containing 100 /aM forskolin 
(Sigma), 1 mM 3-isobutyl-l-methylxanthine (Sigma), 1 mM Ro20- 
2.1. Construction of the ORL(Q28OH) mutant 1724 (Biomol Res.) and the ligand(s) to be tested at the desired con- 
Replacement of glutamine-280 by histidine in the TM6 of ORL1 centration. After exactly 10 min at 37°C, the reaction was stopped by 
addition of 20 ~1 HCI 2.2 N and rapid mixing (Vortex), and the 
was achieved by site-directed mutagenesis, according to Kunkel et al. [3H]cAMP content of each tube was determined by selective batch 
[15], of human ORL1 cDNA fragment HindlII-PstI, cloned in plas- 
mid Bluescript SK + (Stratagene). Uracylated single-strand DNA was elution on acidic alumina columns, essentially as described by Alvarez 
and Daniels [17]. generated in E. coli bacterial strain BW313 with helper phage 
M13KO7 (Invitrogen), and annealed with the 5'-phosphorylated oli- 
gonucleotide 5'-CTGCTGGACGCCTGTGCACGTCTTCGTGCTG- 2.5. Data analysis 
Analysis of the data was performed with the lnPlot ver 4.03 soft- GCC-3' carrying the mutation as well as a silent one, to generate an 
ApaLI restriction site in hORLI cDNA. The double-stranded DNA ware from GraphPad Inc. (San Diego, CA, USA). 
was synthesized and ligated with Sequenase (Pharmacia) and T4 DNA 
ligase (Boehringer Mannheim). Selective amplification of the mutated 3. Results 
DNA was achieved upon transformation i E. coli bacterial strain 
mutL, and the appropriate clones were selected on the basis of ApaLI 
restriction. The mutated cDNA was subcloned in eukaryotic expres- Saturat ion binding studies of the mutant  ORL(Q280H) re- 
sion vector pRc/CMV (Invitrogen) at HindlIl and XbaI sites, after ceptor in membranes from recombinant CHO cells indicated 
sequence verification, that [3H]nociceptin specifically labeled a homogenous popula- 
tion of sites (Bma× in the range 0.8-2 pmol/mg protein, de- 
2.2. Expression in cell lines pending on the preparation) with nearly the same high affinity 
CHO-K1 cells were transfected with pRc/CMV/ORL(Q280H) by (KD = 0.065 + 0.004 nM, n = 3) as it does the wild-type recep- 
the calcium phosphate precipitation method [16] and selected as re- 
sistant to G418 (Gibco BRL; 400 lag/ml), as described earlier [1]. tor (Fig. 1 and Table 1). In addition, the Tyr a analogue of 
Screening of the clones was based on the ability of nociceptin to nociceptin was found to be equally potent in competing with 
inhibit forskolin-induced accumulation of cAMP. For membrane equil ibrium binding of [3H]nociceptin at the native (KI = 0.26 
preparations, cells were harvested, frozen at -70°C for at least 60 nM) and mutant  (KI = 0.38 nM) receptors (Fig. 2 and Table 
min, and homogenized in 50 mM Tris-HCl, pH 7.4 in a Potter Elveh- 
jem tissue grinder. The nuclear pellet was discarded by centrifugation 1). Taken together, these data suggest hat residue Q280 of the 
at 1000×g and the membrane fraction was collected upon centrifuga- ORL1 receptor is not a key component  of the nociceptin 
tion at 100000×g. binding pocket. The ability of various opioid ligands to 
bind the mutated Q280H ORL1 receptor was then examined. 
2.3. Binding experiments The results are shown in Fig. 2 and Table 1. The mutat ion did 
[3H]Nociceptin (23 Ci/mmol), custom-labelled by Amersham, was not seem to improve binding of the ~t-, 5- and ~c-selective used. Binding experiments were performed at 25°C in polypropylene 
tubes. Membranes (30-50 lag) were incubated with the tritiated ligand opioid agonists DAGO,  DTLET  and U50488, respectively. 
and various unlabelled ligands, for 60 min, in 0.5 ml Tris 50 mM, pH At concentrations up to 10 ~tM, these were ineffÉcacious in 
7.4 supplemented with protease-free BSA (0.1 mg/ml final) to avoid competing with binding of [3H]nociceptin. In contrast, the 
adsorption of the radioligand on the walls of the tubes. Non-specific mutat ion resulted in a substantial (5- to > 100-fold) increase 
binding was determined in the presence of 10 -6 M nociceptin. Bound 
radioactivity was collected by filtration on polyethyleneimine-treated of the receptor's apparent affinity for other opioid ligands, 
GF/B filters (Whatman), and counted in a Kontron model MR300 including etorphine and diprenorphine, lofentanil, the ~-selec- 
liquid scintillation counter, tive agonist dynorphin A and the ~¢-selective antagonist nor- 
binaltorphimine (nor-BNI). Most pronounced was the effect 
2.4. Assay for intracellular cAMP of the mutat ion on binding of the antagonists nor-BNI and 
Sterile hemolysis tubes were seeded with 2 x 105 recombinant CHO 
cells in culture medium and incubated for about 16 h at 37°C. The diprenorphine, whose apparent affinities were augmented 
culture medium was removed and 200 Ixl fresh medium containing 0.1 more than 100-fold. In other words, the Q280H mutat ion 
~M adenine and 0.6 I.tCi [3H]adenine (24 Ci/mmol, Amersham) was definitely endowed the ORLI  receptor with improved opioid 
added. After 1 h at 37°C, the cells were rinsed with 400/al of HEPES- receptor binding characteristics and, in this sense, could be 
buffered Krebs-Ringer saline (KRH: 124 mM NaC1, 5 mM KC1, 1.25 considered a gain-of-function mutation. mM MgSO4, 1.5 mM CaC12, 1.25 mM KH2PO4, 25 mM HEPES, 
8 mM glucose, 0.5 mg/ml BSA; pH 7.4) and 180 ~tl of fresh KRH The ability of the mutant  receptor to mediate inhibit ion of 
was added to each tube. Intracellular accumulation of cAMP was forskolin-induced accumulation of cAMP in recombinant 
Table 1 
Comparison of the binding properties and cyclase inhibition potencies of diverse ligands, in CHO cells stably expressing the wild-type or mu- 
tant ORL(Q280H) receptor 
Binding (Ki, nM) cAMP (EDs0, nM) 
Wild-type ORL(Q280H) Wild-type ORL(Q280H) 
Nociceptin 0.13 + 0.01 (n = 3) 0.38 + 0.02 (n = 4) 0.84 + 0.02 (n = 4) 3.06 ~ + 0.12 (n = 8) 
[Tyr l]-nociceptin 0.26 + 0.01 (n = 2) 0.37 + 0.05 (n = 2) 1.19 + 0.09 (n = 3) 2.44 ~ + 0.1 (n = 3) 
Lofentanil 24.2 _+ 0.26 (n = 3) 3.1 + 0.07 (n = 2) 6.67 _+ 0.23 (n = 2) 44 b + 3.77 (n = 6) 
Etorphine 530+40 (n=3) 35+2.4 (n=4) 400+48 (n=3) 560c+182 (n=3) 
DynorphinA 111+9 (n=3) 21+3.6 (n=3) >10000 551c+66 (n=3) 
Nor-BNI >10000 74+10 (n=3) >10000 ~ >10000 d 
Diprenorphine > 10000 137 + 17 (n = 3) > 10000 ~ > 10000 d
DAGO > 10 000 > 10 000 > I 0 000 ~ > 10 000 ~ 
DTLET > 10000 > 10000 > 10000 e > 10000 ~ 
U-50488 > 10000 > 10000 > 10000 e > 100006 
Values are means + S.E.M. 
~ > 75% maximal inhibition, b60% maximal inhibition, c20-30% maximal inhibition, dantagonist, einactive. 
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opioid binding pocket within the non-opioid ORL1 receptor. 
Mutation to Ala of the His residue, which is present at the 
Bma x -- 1.7 pmol /mg prote in  equivalent position in the three opioid receptor types, dramat- 
ically reduces binding of the la-selective agonist [:~H]DAGO 
95  KD = 0 .07  nM and antagonist [aH]naloxone to the g-opioid receptor [12], 
I and a 3-D model of the g-opioid receptor complexed with 
lofentanil has proposed that this residue may be a constituent 
of the opioid binding pocket [18]. Indeed, the mutant 
ORLI(Q280HI receptor, although it retains the same high c~ 20  • 
E affinity as the native receptor for nociceptin, displayed signifi- 
--~" cantly increased (5- to > 100-fold) affinity for the non-selec- 
E 
tive opioid agonists (etorphine, lofentanil) and antagonist (di- 
e prenorphine) as well as for the ~c-selective agonist dynorphin 
eL_ 15 • A and antagonist Nor-BN1. In these respects, the mutation 
t_t_ • appears to have shifted the pharmacological profle of the 
ORL1 receptor towards that of a ~c-opioid receptor. However, c- 
U50488, a ~c-selective compound of the arylacetamide s ries, 
o 10 failed to recognize the mutant receptor. This discrepancy 
could be explained by the fact that determinants specifically 
• • required for binding of U50488 [19] are lacking in the ORE1 
receptor. Moreover, peptide and non-peptide ligands appear 
to bind opioid receptors differently [19,20], the exofacial loops 
5 • filtering access of the former but not of the latter, to the 
• opioid binding pocket. The fact that the mutant 
ORLI(Q280H) receptor failed to bind the bt- and &selective 
i i peptides, DAGO and DTLET respectively, could readily be 
0.5 1.© 1.5 explained by the extracellular loops of ORLI preventing bind- 
Bound [aH]nociceptin ing of receptor type-selective opioid ligands via an exclusion 
(pmol/mg protein) mechanism, as proposed by Metzger and Ferguson [211. In 
contrast, dynorphin, taking advantage of its basic, 'address" 
Fig. 1. Scatchard analysis of [aH]nociceptin binding to membranes core, could bypass the filter by interacting with the negatively 
of CHO cells stably expressing the mutant receptor ORL(Q280H). charged second extracellular loop of OR[,I, as it does at the 
~-opioid receptor [19,20,22]. 
More recently, Uhl et al. [23] reported that the His residue 
CHO cells was then explored. Fig. 3 shows that nociceptin in TM6 of the bt-opioid receptor could be replaced by Gin 
and [Tyrl]nociceptin caused maximal (75 80%) inhibition with minimal consequences on binding of la-selective ligands, 
(Fig. 3), however with slightly (2 3-fold) reduced apparent indicating that g-selective drug recognition may simply de- 
affinity compared to the wild-type receptor (Table 1). Surpris- 
ingly, lofentanil, etorphine and dynorphin A, which totally 
displaced binding of [aH]nociceptin in competition experi- • nociceptin 
ments (Fig. 2), inhibited cAMP production only partially O Tyrl-noclcept,n 
(Fig. 3), hence acted as partial agonists at the mutant recep- o qofentan,I 
tor. The most pronounced effect was with etorphine which, lOO • etorphme A diprenorpblne 
although maximally (>  90% inhibition) active via the wild- ~ • Nor BNI 
type ORL1 receptor, caused a maximum 20-30% inhibition c~ rq dynorphin A 
of forskolin-induced accumulation of cAMP in cells expres- c 
sing the mutant ORL(Q280H) receptor. Likewise, dynorphin 
A, despite a relatively high apparent affinity for the mutant ~ ' 
receptor  (K i ~ 20 nM), was somewhat ineffective in inhibiting ~°~ 
adenylate cyclase. In the presence of 10 gM etorphine or ~ s0 
dynorphin A, the potency of nociceptin to inhibit residual ~ 
(about 50% of maximally inhibitable) cyclase activity via the ~- 
mutant receptor was decreased, as revealed by a shift towards 
the right of nociceptin's dose response curves (Fig. 4). This 
confirmed the notion that etorphine and dynorphin A acted as 
mixed agonists-antagonists a  the mutant (Q280H) receptor. 
i0 -9 8 -7 -6 -5 
4. Discussion l unlabelled hgand], (IogM) 
Fig. 2. Inhibition of [aH]nociceptin (1 nMI binding by selected 
Replacement of residue Gln 2s° by His in the sixth putative opioid and non-opioid ligands in membranes from CHO cells stably 
membrane-spanning domain of ORL1 was achieved here to expressing the mutant receptor ORL(Q280H). Each point represents 
improve the receptor's affinity for opioid ligands, i.e. create an the mean +_ S.E.M. from 2 6 determinations performed in duplicate. 
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ORLI ORLI  (Q280H)  
I • noc icept in  
n O Tyr l -noc icept in  
100 0 Io fentan i l  
~u r "  100 ~ x • e torph ine  
46 A dynorph in  A 
o 
e 
g ~ 50 5o 
g 
] 
,,o 
0 t J i t t t 0 i t t t i t 
-i0 -9 -8 -7 -6 -5 -i0 -9 -8 -7 -6 -5 
[ l igand] ,  (IogN1) [ l igand] ,  (Iogtvl) 
Fig. 3. Compared inhibition of forskolin-induced accumulation f cAMP by selected opioid and non-opioid ligands in intact CHO cells stably 
expressing the wild-type or mutant ORL(Q280H) receptor. Each point represents the mean + S.E.M. from at least 3 experiments performed in
triplicate. 
pend on the presence of an E-nitrogen atom at this position. ] 
Likewise, the present study shows that the inverse substitution I o. ,Oln .is, on minor hanges i nocic ptin 
binding, while conferring reater affinity for opioid ligands, o 
Taken together, these results act more in favor of the require- ~'N~ T 
ment of an E-nitrogen at this position in the TM6 of opioid 
receptors and, perhaps, nociceptin receptors, rather than the -~ o c ~.  I ~ etorphine 10uM 
His residue being one discriminative determinant between ~ ! ~ ~ ~ /  
opioid receptors and ORL. This would explain why, even in 
the absence of histidine, opioid ligands such as etorphine and 
lofentanil could interact with ORL (Table 1). 
The mutant ORLI(Q280H) receptor appeared to be fully o 
functional, mediating robust (->75%) inhibition of adenylyl 
cyclase by nociceptin and its Tyr I analogue. Surprisingly how- -~ 50r J \ ~k .a-~ 
ever, the opioid agonists, especially etorphine and lofentanil, u ~ I . . .1 . . . . .  ~ ~ 
which acted as low affinity, full agonists of the ORL1 recep- ~ 
tor, behaved as higher affinity, partial agonists and even an- ~ ] +dynorohin A lOlaM ~ 
tagonists of the mutant receptor, as if the mutation had cre- -- 
ated an opioid antagonist binding pocket within the ORL1 
receptor. This conclusion is sustained by the fact that the L 
Gln~ His mutation in ORL1 increases most the affinities of 
the antagonists diprenorphine and nor-BNI, and that these 
remain antagonists at the mutant receptor. By contrast, it 
has been observed that exchange of the histidine by alanine 0 i m i J B 
in TM6 of the p-opioid receptor impaired opioid binding -10 -9  -8  -7  -6  
while enhancing intrinsic activity [12]. Taken together, these [noc icept in ] ,  (IogM) 
data suggest hat the His residue in TM6 of opioid receptors 
is not only implicated in recognition of opioid ligands, partic- Fig. 4. Inhibition of the forskolin-stimulated cAMP content by noci- 
ceptin in the absence or presence of 10 laM dynorphin A or etor- 
ularly antagonists, but may also control coupling with G- phine. The ED~0 of nociceptin was increased from 3 nM to 13 nM 
proteins. Similar conclusions have been reached for other pep- and 56 nM in the presence of dynorphin A and etorphine respec- 
tide hormone receptors in which His residues in TM5 or 6 tively. 
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could be replaced by Gln without major effects, while other [7] Lachowicz, J.E., Shen, Y., Monsma, F.J. and Sibley, D.R. (1995) 
J. Neurochem. 64, 3440. 
substitutions impaired more selectively antagonists binding [8] Wick, M.J., Minnerath, S.R., Roy, S., Ramakrishnan, S. and 
[24-26]. Loh, H.H. (1995) Mol. Brain Res. 32, 342 347. 
In summary, the Q280H mutation of the ORL1 receptor, [9] Meunier, J.CI., Mollereau, C., Toll, L., Suaudeau, Ch., Moisand, 
while not affecting the structure and functionality of the bind- Ch., Alvinerie, P., Butour, J.L., Guillemot, J.CI., Ferrara, P., 
ing pocket for its natural peptide agonist, nociceptin, results Monsarrat, B., Mazarguil, H., Vassart, G.. Parmentier, M. and 
Costentin, J. (1995) Nature 377, 532 535. 
in improved affinity for certain opioid ligands, especially an- [10] Reinscheid, R.K., Nothacker, H.P., Bourson, A., Ardati, A., 
tagonists. This mutation emphasizes a role of the His residue Henningsen, R.A., Bunzow, J.R., Grandy, D.K., Langen, H., 
in TM6 of opioid receptors in maintaining an opioid receptor Monsma, F.J. and Civelli, O. (1995) Science 270, 792 794. 
antagonist conformation. At present it is not known whether [11] Kong, H., Raynor, K., Yasuda, K., Moe, S.T., Portoghese, P.S., 
Bell, G.I. and Reisine, T. (1993) J. Biol. Chem. 268, 23055 the corresponding residue (Gln) in TM6 of the ORLI  receptor 23058. 
plays a similar role. The answer to this question will await [12] Surratt, C.K., Johnson, P.S., Moriwaki, A.. Seidleck, B.K., Bias- 
further mutagenesis tudies on the ORL1 receptor and the chak, C.J., Wang, J.B. and Uhl, G.R.. (1994) J. Biol. Chem. 269, 
development of other ligands, especially antagonists, 20548 20553. 
[13] Befort, K., Tabbara, L., Bausch, S., Chavkin, C., Evans. C. and 
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